Leukaemia is a type of blood cancer that usually affects white blood cells and bone marrow. White blood cells are an important part of your immune system that fight infection, and bone marrow is where blood cells like these are made.
There are many different types of leukaemia. Some types develop faster, and are known as acute leukaemia. These include acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), acute premyelocytic leukaemia (APL), and B or T-cell acute lympoblastic leukaemia.
But each type of leukaemia acts differently, and will need to be treated differently.
Around 2,420 people are diagnosed with acute myeloid leukaemia (AML) every year.
AML affects cells involved in the production of a family of blood cell called myeloid cells, which include red blood cells, platelets and certain types of white blood cells.
We don’t have a lot of treatment options for AML, and it can be hard to treat, especially in older people who have a higher risk of developing the disease. Standard treatment is chemotherapy, and stem cell transplant is usually considered if chemotherapy fails or people relapse after initially responding to treatment.
Because there are limited avenues of treatment, and at the moment we don’t have any targeted therapies for AML, this is a type of blood cancer where our research investment is high.
Our portfolio of research spans from finding where the roots of AML lie - so we can combat the disease right from the beginning - to testing new treatments for people living with AML.